Glenmark expands diabetes portfolio with new Empagliflozin treatments

Table of Content


Glenmark Pharmaceuticals announced today the launch of Empagliflozin and its fixed-drug combinations in India under the brand names Glempa, Glempa-L, and Glempa-M.

The shares of Glenmark Pharmaceuticals Limited were trading today at ₹1,390.85 up by ₹9.35 or 0.67 per cent on the NSE today at 12.37 pm.

The SGLT2 inhibitor and its combinations are designed to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) while reducing cardiovascular risks. Clinical trials have shown Empagliflozin reduces major cardiovascular events by 14 per cent in T2DM patients with high CV risks.

“Glenmark has a strong legacy of introducing innovative and accessible treatments for Cardiometabolic care in India,” said Alok Malik, President and Head of India Formulations Business. “The launch of Glempa range reinforces this commitment by providing a comprehensive and affordable solution.”

The Glempa product line includes three options: Glempa (Empagliflozin 10mg/25mg) as a standalone treatment, Glempa-L (Empagliflozin with Linagliptin) as a dual-action therapy, and Glempa-M (Empagliflozin with Metformin) for stronger glycemic control.

According to IQVIA data, the market for Empagliflozin and combinations in India was valued at 642 crore for the 12-month period ending January 2025.

This launch follows Glenmark’s 2024 introduction of Lirafit, a biosimilar for Liraglutide, marking the company’s entry into the injectable anti-diabetic market as part of its expanding cardiometabolic portfolio.





Source link

AIMPWA

mmkrishnandasu@gmail.com http://msmenews.sbs

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent News

Trending News

Editor's Picks

Big city pull: Easing migration will be tough, say experts

The demand-supply gap of workers across states is skewed and unless there is an immediate impact of agricultural reforms and infrastructure development, the Union budget’s aim to ease migration will be a tough task, recruiters warned. In the budget for fiscal 2025-26, the government said it aims to generate new businesses and employment for young,...

Insurance reforms: Govt to further relax foreign investment rules while raising FDI limit to 100%

The government plans to further liberalise foreign investment rules for insurance companies by removing the condition that mandates the presence of Indian residents in the boards and top management of insurance entities, said top finance ministry officials. The insurance reforms bill will be introduced in the ongoing budget session of parliament, one of these officials...

ALL INDIA MSMES PROMOTION AND WELFARE ASSOCIATION

Quick Links

Popular Categories

Must Read

AIMPWA © 2025- All Right Reserved. Designed and Developed by  growGX.com